Medtronic gets FDA panel date for minimally invasive lower back spinal stabilization; Novocure releases positive second-line combo data;

@FierceMedDev: ICYMI Friday: Bard to buy Liberator for $181M to improve access to home care market. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Scientific earns CE mark for second-gen Watchman implant to prevent stroke. More | Follow @VarunSaxena2

@EmilyWFierce: ICYMI Friday: Cancer diagnostics company closes up shop after 6-year FTC investigation. Article | Follow @EmilyWFierce

> The FDA has given Medtronic a Feb. 19 advisory panel date to review its PMA for DIAM Spinal Stabilization System to treat lower back pain due to moderate lumbar degenerative disc disease. More

> Startup B-Temia has started a pivotal U.S. trial for its powered assistive Demoskeleton technology called Keeogo exoskeleton to improve mobility. It plans to submit for FDA clearance next year. More

> Novocure ($NVCR) has disclosed positive combination second-line data for its Optune as a second-line treatment in combination with chemotherapy to treat first recurrence of glioblastoma. More

Biotech News

@FierceBiotech: With Pfizer and Allergan set for a $160B megamerger, what becomes of R&D? Report | Follow @FierceBiotech

@JohnCFierce: So Ian Read remains CEO. Gets $AGN at a pretty decent price, Gets his Irish domicile. Looking for $2B in cuts. Read must be pretty chuffed. | Follow @JohnCFierce

@DamianFierce: I thought Ian Read would be taller. Item | Follow @DamianFierce

> Roche's blockbuster-hopeful immunotherapy shows promise in skin cancer. Report

> ObsEva taps A-list investors for $60M as pipeline nears late-phase trials. Article

Pharma News

@FiercePharma: CBN: Multinational drugmakers face uphill battle in China. FiercePharmaAsia story | Follow @FiercePharma

@CarlyHFierce: UPDATED: Pfizer finally gets its inversion with $160B Allergan megamerger agreement. Article | Follow @CarlyHFierce

> Takeda's Velcade successor gets quick FDA approval. Item

> Amgen's Repatha scores an exclusive with CVS. Story

> Novartis scores new approvals for Cosentyx in Europe. Article

Animal Health News

> Virginia Tech preps dog trial of new method to improve glioblastoma treatment. Report

> Zoetis ups the ante in prevention with new flu vaccine and flea fighter for dogs. More

> Oasmia chairman is optimistic about animal health despite downsized IPO. Story

> Kuddly joins herd of veterinary apps with $1.5M seed round. Item

> Taco Bell joins fast food peers with cage-free egg pledge. Article

Biotech IT News

> Molecular Health raises $27M to advance data-crunching tech. News

> Illumina to make 5,000-genome autism database available through BaseSpace. Report

> Amazon shares landmark cancer genome data sets on cloud platform. Story

> FDA gives scientists freedom to tweet in long-awaited social media policy. Item

> AstraZeneca inks deal to install robots at new R&D facility. Article

Pharma Marketing News

> Amgen nabs another PCSK9 exclusive, this time with giant CVS. Report

> Better together? Savvy e-patients may make pharma marketing smarter. Story

> Teva goes for laughs in new social media campaign for COPD. Item

> AstraZeneca aims at a 'broader' target with services-based lung cancer effort. Article

> Healthcare ad and media agencies break into annual 'best workplaces' ranking. More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.